Publications

Export 115 results:
Auteur [ Title(Desc)] Type Année
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Therriault J, Pascoal TA, Sefranek M, Mathotaarachchi S, Benedet AL, Chamoun M, Lussier FZ, Tissot C, Bellaver B, Lukasewicz PS et al..  2021.  Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia.. Ann Clin Transl Neurol. 8(10):2083-2092.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ongali B, Nicolakakis N, Tong X-K, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H, Hamel E.  2014.  Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.. Neurobiol Dis. 68:126-36.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas É, Kang MSu, Lussier F, Tissot C et al..  2020.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies.. Mol Psychiatry.
Picard C, Nilsson N, Labonte A, Auld D, Rosa-Neto P, Ashton NJ, Zetterberg H, Blennow K, Breitner JCS, Villeneuve S et al..  2021.  Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.. Alzheimers Dement.
Boyle AJ, Gaudet VC, Black SE, Vasdev N, Rosa-Neto P, Zukotynski KA.  2021.  Artificial intelligence for molecular neuroimaging.. Ann Transl Med. 9(9):822.
Tissot C, Therriault J, Pascoal TA, Chamoun M, Lussier FZ, Savard M, Mathotaarachchi SS, Benedet AL, Thomas EM, Parsons M et al..  2021.  Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease.. Alzheimers Dement (N Y). 7(1):e12154.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Bellaver B, Ferrari-Souza JPedro, da Ros LUglione, Carter SF, Rodriguez-Vieitez E, Nordberg A, Pellerin L, Rosa-Neto P, Leffa DTeixeira, Zimmer ER.  2021.  Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.. Neurology.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.

Pages